Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in…
Kite, a Gilead Company announces that the European Commission (EC) has granted approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with…
Read More...
Read More...
